| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | SHP; SHP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human NR0B2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NR0B2抗体的3篇文献概览，包含文献名称、作者及摘要内容简述：
---
1. **文献名称**：*"Development and Characterization of a Monoclonal Antibody Specific for Human NR0B2 (SHP)"*
**作者**：Zhang Y, et al.
**摘要**：本研究开发了一种针对人NR0B2蛋白的单克隆抗体，并通过Western blot和免疫组化验证其特异性。该抗体成功应用于肝组织样本中NR0B2的表达定位，证实其在代谢相关疾病研究中的实用性。
2. **文献名称**：*"NR0B2 Antibody-Based Detection of Transcriptional Repression Activity in Bile Acid Homeostasis"*
**作者**：Lee SS, et al.
**摘要**：利用NR0B2抗体进行染色质免疫沉淀(ChIP)和共免疫沉淀实验，揭示了NR0B2通过与FXR(法尼醇X受体)相互作用抑制胆汁酸合成基因的分子机制，为代谢调控提供新见解。
3. **文献名称**：*"Validation of NR0B2 as a Therapeutic Target in Obesity-Related Metabolic Dysfunction via Antibody-Mediated Inhibition"*
**作者**：Thompson JR, et al.
**摘要**：研究通过阻断性NR0B2抗体在小鼠模型中抑制其功能，发现NR0B2活性降低可改善胰岛素敏感性和脂质代谢紊乱，提示其作为代谢性疾病治疗靶点的潜力。
---
**注**：以上文献为示例，实际引用需核对具体论文信息。如需真实文献，建议通过PubMed或Google Scholar检索关键词“NR0B2 antibody”或“SHP antibody”获取最新研究。
The nuclear receptor subfamily 0 group B member 2 (NR0B2), also known as Small Heterodimer Partner (SHP), is an atypical orphan nuclear receptor lacking a DNA-binding domain. It functions as a transcriptional regulator by interacting with other nuclear receptors (e.g., LRH-1. FXR, HNF4α) and repressing their activity. NR0B2 plays a critical role in metabolic pathways, including bile acid synthesis, cholesterol homeostasis, glucose metabolism, and hepatic lipogenesis. Its dysregulation is associated with metabolic disorders, liver diseases, and cancer.
NR0B2 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore NR0B2's regulatory mechanisms in tissues, particularly the liver and intestines. Researchers also employ these antibodies to investigate its role in diseases such as non-alcoholic fatty liver disease (NAFLD), diabetes, and obesity.
Commercially available NR0B2 antibodies are typically raised against specific epitopes of human or mouse NR0B2 proteins. Validation includes reactivity checks across species, specificity confirmation via knockout controls, and application-specific performance testing. These antibodies support both basic research and therapeutic development, as NR0B2 is considered a potential drug target for metabolic syndrome and cholestatic liver disorders.
×
